Analysts expect Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) to report $70,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aurinia Pharmaceuticals’ earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $30,000.00. Aurinia Pharmaceuticals reported sales of $30,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 133.3%. The business is expected to announce its next quarterly earnings results on Thursday, March 21st.

According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year sales of $490,000.00 for the current year, with estimates ranging from $460,000.00 to $500,000.00. For the next financial year, analysts expect that the business will report sales of $170,000.00, with estimates ranging from $100,000.00 to $300,000.00. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Aurinia Pharmaceuticals.

Get Aurinia Pharmaceuticals alerts:

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The firm had revenue of $0.38 million during the quarter, compared to the consensus estimate of $0.07 million. Aurinia Pharmaceuticals had a negative net margin of 7,280.85% and a negative return on equity of 36.10%.

Several analysts recently weighed in on AUPH shares. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Wednesday, January 9th. BidaskClub upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 5th. Cantor Fitzgerald set a $18.00 price objective on Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 1st. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, September 26th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $12.15.

A number of institutional investors and hedge funds have recently bought and sold shares of AUPH. FMR LLC grew its stake in Aurinia Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after purchasing an additional 95,650 shares during the last quarter. Franklin Resources Inc. grew its stake in Aurinia Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after purchasing an additional 105,300 shares during the last quarter. Jane Street Group LLC purchased a new position in Aurinia Pharmaceuticals in the third quarter valued at about $182,000. Finally, Virtu Financial LLC purchased a new position in Aurinia Pharmaceuticals in the fourth quarter valued at about $105,000. Institutional investors own 25.17% of the company’s stock.

AUPH stock opened at $7.55 on Monday. The stock has a market capitalization of $644.34 million, a P/E ratio of -8.21 and a beta of 1.66. Aurinia Pharmaceuticals has a 1-year low of $4.76 and a 1-year high of $7.85.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.